It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase comparative study to evaluate the efficacy and safety of QL2108 to Dupixent in adult subjects with moderate-to-severe atopic dermatitis. A total of 520 subjects are planned to be included and randomized at a ratio of 1:1 to receive QL2108 injection or Dupixent